FDA Develops Separate Set Of GMP Requirements For PET Drug Makers
Executive Summary
FDA will require commercial manufacturers of approved positron emission tomography drugs to meet new GMP requirements by Dec. 12, 2011. This marks the first time that FDA has mandated separate GMPs for a particular type of drug product
You may also be interested in...
PET Drugs Without An IND Get Three More Years For Studies Under FDA Guidance
Q&A document from agency says sponsor does not have to use the same manufacturing process as the reference listed drug.
FluoroPharma’s Bet On Next-Gen Molecular Imaging Agents
Molecular imaging’s technological advances are impressive, but getting the business model right and investors on board has been hard for start ups in the field. FluoroPharma CEO Thijs Spoor believes his company, which has several cardiovascular imaging agents in clinical trials, is on the right track and ripe for partnerships.
Supply Chain GMP Rewrite, Guidance Documents in Works at FDA
FDA is continuing to draft a regulation for strengthening supply chain controls that he had announced in June 2010, Brian Hasselbalch of the agency’s center for drugs told a Parenteral Drug Association conference last month.